An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer.

The immune metastatic risk score addresses important challenges in the treatment of cervical cancer - identifying patients at high risk of DM after radiotherapy. The findings of this study indicate that high tumor mutational burden and a 'cold', immune-excluded tumor microenvironment influence distant metastatic recurrence. Further validation of the risk score is needed.